Financials
Interim Results | Sep. 30, 2024 |
Interim Results | Sep. 28, 2023 |
Results for the year ended 31 December 2022 | Apr. 27, 2023 |
Interim results | Sep. 28, 2022 |
Results for the year ended 31 December 2021 | May. 30, 2022 |
Interim Results | Sep. 30, 2021 |
Proxies
Result of AGM | Jun. 24, 2024 |
Notice of Annual General Meeting | Jun. 03, 2024 |
Result of AGM | Jun. 28, 2023 |
Result of AGM | Jun. 27, 2022 |
Posting of Annual Report and Notice of AGM | Jun. 01, 2022 |
Notice of AGM | Jun. 07, 2021 |
Ownership Update
Holding(s) in Company | Sep. 16, 2024 |
Holding(s) in Company | May. 13, 2024 |
Holding(s) in Company | Apr. 23, 2024 |
Issue of Options in lieu of salary increases | Mar. 07, 2023 |
Holding(s) in Company | Feb. 22, 2023 |
Holding(s) in Company | Feb. 06, 2023 |
Holding(s) in Company | Jan. 24, 2023 |
Announcements
Appointment of Professor Dawn Coverley as CSO | Jan. 02, 2025 |
Execution of Agreement for North America | Oct. 21, 2024 |
Update on Licensing and Partnership Agreement | Oct. 03, 2024 |
Collaboration with Moffitt Cancer Center | Sep. 09, 2024 |
Update on Strategic Partnership in North America | Jul. 25, 2024 |
Manufacturing Agreement with BBI Solutions | Jul. 18, 2024 |
Issue of Share Options in Lieu of Consultancy Fees | Jul. 09, 2024 |
Prospectuses
Prospectus in relation to the Proposed Subscription of 35,666,665 New Ordinary Shares at 1.5p per share. | Sep. 21, 2022 |
Cizzle Biotechnology Holdings plc - Single prospectus | Sep. 21, 2022 |